Immunoreactivity to Cetuximab in Cancer Patients
|ClinicalTrials.gov Identifier: NCT00896896|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : April 2, 2013
RATIONALE: Studying samples of blood in the laboratory may help doctors predict which patients will develop hypersensitivity to cetuximab.
PURPOSE: This research study is looking at hypersensitivity to cetuximab in patients with head and neck cancer or advanced colorectal cancer previously treated with cetuximab.
|Condition or disease||Intervention/treatment|
|Colorectal Cancer Head and Neck Cancer||Other: immunologic technique Other: laboratory biomarker analysis|
- To examine serum samples from patients with head and neck cancer or advanced colorectal cancer previously treated with cetuximab for the presence of antibodies against cetuximab.
OUTLINE: Serum samples are examined by immunoreactivity screening of IgE, IgG, IgA, and IgM antibodies and complement reaction.
|Study Type :||Observational|
|Actual Enrollment :||538 participants|
|Official Title:||Immunoreactivity to Cetuximab in Cancer Patients|
|Study Start Date :||November 2006|
|Primary Completion Date :||October 2008|
|Study Completion Date :||October 2008|
Other: immunologic technique
- Identification of antibodies (e.g., IgE, IgG, IgA, and IgM) against cetuximab [ Time Frame: Until all samples are collected. ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00896896
|Principal Investigator:||Barbara Murphy, MD||Vanderbilt-Ingram Cancer Center|